Co-operation between anti-cancer treatment and palliative care in lung cancer patients

がん患者と対症療法 Vol.22 No.2, 13-17, 2011



Recently, therapeutic strategies for lung cancer have drastically changed. Molecular-targeted drugs have enabled “personalized anti-cancer therapy”, in which a more effective therapy associated with few adverse reactions can be selected for each patient. In addition, TNM classification has been revised. Furthermore, introduction of novel antiemetics has made platinum preparations more accessible. Regarding palliative care for common and refractory symptoms in patients with lung cancer, guidelines have recently been issued on analgesic adjuvants for neuropathic pain and morphine for dyspnea. By establishing a 3-level triage system involving primary, secondary, and tertiary palliative care, limited resources for palliative care can be effectively utilized. Palliative care providers should also learn the new trends in anticancer therapy, thereby enabling seamless collaboration between anticancer treatment and palliative care.




診療ガイドライン UP-TO-DATE 掲載開始